$HALO
HALOZYME THERAPEUTICS, INC.

2022 Q4 Form 10-Q Financial Statement

#000115903622000059 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2022 Q2
Revenue $181.5M $209.0M $152.4M
YoY Change 77.93% 80.42% 11.66%
Cost Of Revenue $42.12M $47.32M $33.94M
YoY Change 95.12% 154.55% 47.46%
Gross Profit $139.4M $161.7M $118.4M
YoY Change 73.32% 66.24% 4.39%
Gross Profit Margin 76.79% 77.36% 77.72%
Selling, General & Admin $36.35M $34.47M $57.48M
YoY Change 163.9% 161.73% 366.49%
% of Gross Profit 26.08% 21.32% 48.53%
Research & Development $22.57M $16.71M $15.48M
YoY Change 123.25% 96.85% 91.88%
% of Gross Profit 16.19% 10.33% 13.07%
Depreciation & Amortization $4.552M $2.000M $12.55M
YoY Change 488.87% 185.71% 1468.25%
% of Gross Profit 3.27% 1.24% 10.59%
Operating Expenses $63.47M $51.17M $84.36M
YoY Change 165.75% 136.31% 313.74%
Operating Profit $75.91M $83.29M $34.06M
YoY Change 34.27% 10.2% -63.39%
Interest Expense -$3.718M $7.514M -$4.049M
YoY Change 115.66% 328.39% -331.11%
% of Operating Profit -4.9% 9.02% -11.89%
Other Income/Expense, Net $641.0K -$945.0K
YoY Change 133.94% -527.6%
Pretax Income $70.79M $73.71M $30.01M
YoY Change 29.16% -0.54% -67.21%
Income Tax $13.09M $12.10M $7.326M
% Of Pretax Income 18.49% 16.42% 24.41%
Net Earnings $57.70M $61.63M $22.69M
YoY Change -13.58% -71.54% -75.2%
Net Earnings / Revenue 31.79% 29.49% 14.89%
Basic Earnings Per Share $0.45 $0.16
Diluted Earnings Per Share $0.41 $0.44 $159.5K
COMMON SHARES
Basic Shares Outstanding 135.2M shares 136.5M shares 137.9M shares
Diluted Shares Outstanding 139.4M shares 142.2M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $362.8M $265.6M $209.4M
YoY Change -51.03% -67.45% -72.28%
Cash & Equivalents $234.2M $147.2M $90.93M
Short-Term Investments $128.6M $118.4M $118.4M
Other Short-Term Assets $45.02M $51.04M $45.60M
YoY Change 11.22% 53.26% 39.47%
Inventory $100.1M $103.3M $97.62M
Prepaid Expenses $51.69M $47.78M
Receivables $231.1M $233.3M $179.4M
Other Receivables $0.00 $9.985M $9.985M
Total Short-Term Assets $739.0M $653.2M $541.9M
YoY Change -20.22% -35.79% -45.79%
LONG-TERM ASSETS
Property, Plant & Equipment $35.10M $31.07M $37.09M
YoY Change 416.88% 333.73% 266.08%
Goodwill $409.0M $199.5M $199.5M
YoY Change
Intangibles $546.7M $948.9M
YoY Change
Long-Term Investments
YoY Change
Other Assets $71.23M $26.28M $26.78M
YoY Change -57.94% -83.42% 67.59%
Total Long-Term Assets $1.102B $1.211B $1.239B
YoY Change 518.89% 620.52% 4646.49%
TOTAL ASSETS
Total Short-Term Assets $739.0M $653.2M $541.9M
Total Long-Term Assets $1.102B $1.211B $1.239B
Total Assets $1.842B $1.865B $1.781B
YoY Change 66.74% 57.29% 73.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.69M $18.17M $12.23M
YoY Change 1048.15% 446.84% 168.07%
Accrued Expenses $96.52M $74.32M $84.10M
YoY Change 294.89% 305.33% 336.34%
Deferred Revenue $3.246M
YoY Change 85.91%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $13.33M $13.32M $99.05M
YoY Change -85.09% -85.08% 11.08%
Total Short-Term Liabilities $130.8M $109.4M $199.5M
YoY Change 11.65% -3.33% 74.63%
LONG-TERM LIABILITIES
Long-Term Debt $1.493B $1.491B $1.147B
YoY Change 89.62% 89.6% 46.02%
Other Long-Term Liabilities $30.43M $5.418M $138.3M
YoY Change 5494.3% 236.73% 6000.13%
Total Long-Term Liabilities $1.523B $1.497B $1.285B
YoY Change 93.35% 92912.68% 56601.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $130.8M $109.4M $199.5M
Total Long-Term Liabilities $1.523B $1.497B $1.285B
Total Liabilities $1.654B $1.606B $1.488B
YoY Change 82.77% 1299.38% 1177.24%
SHAREHOLDERS EQUITY
Retained Earnings $143.2M $85.52M
YoY Change -343.1% -168.04%
Common Stock $27.50M $13.31M
YoY Change -89.28% -96.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $169.8M $96.99M $293.2M
YoY Change
Total Liabilities & Shareholders Equity $1.842B $1.865B $1.781B
YoY Change 66.74% 57.29% 73.65%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2022 Q2
OPERATING ACTIVITIES
Net Income $57.70M $61.63M $22.69M
YoY Change -13.58% -71.54% -75.2%
Depreciation, Depletion And Amortization $4.552M $2.000M $12.55M
YoY Change 488.87% 185.71% 1468.25%
Cash From Operating Activities $82.45M $69.64M $40.23M
YoY Change -0.08% -42.8% 9.06%
INVESTING ACTIVITIES
Capital Expenditures $2.344M -$1.008M -$968.0K
YoY Change -1583.54% 103.23% 92.45%
Acquisitions
YoY Change
Other Investing Activities $598.0K $0.00 -$434.0M
YoY Change -100.2% -100.0% 884.9%
Cash From Investing Activities -$1.746M -$1.008M -$434.9M
YoY Change -99.42% -94.05% 875.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $109.8M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.329M -12.40M 367.8M
YoY Change -104.06% -79.36% -921.83%
NET CHANGE
Cash From Operating Activities 82.45M 69.64M 40.23M
Cash From Investing Activities -1.746M -1.008M -434.9M
Cash From Financing Activities 6.329M -12.40M 367.8M
Net Change In Cash 87.04M 56.23M -26.90M
YoY Change -123.34% 25.74% -48.69%
FREE CASH FLOW
Cash From Operating Activities $82.45M $69.64M $40.23M
Capital Expenditures $2.344M -$1.008M -$968.0K
Free Cash Flow $80.11M $70.64M $41.19M
YoY Change -3.1% -42.21% 10.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001159036
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2021Q4 us-gaap Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
P3Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32335
dei Entity Registrant Name
EntityRegistrantName
HALOZYME THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0488686
dei Entity Address Address Line1
EntityAddressAddressLine1
11388 Sorrento Valley Road
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
794-8889
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
HALO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
135213058 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147159000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118719000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
118425000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
622203000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
233302000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
90975000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
103276000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
53908000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
51039000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
40482000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
653201000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
926287000 usd
CY2022Q3 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
36674000 usd
CY2021Q4 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
8794000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
25783000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
13414000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
199481000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
0 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
948904000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 usd
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
155434000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 usd
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 usd
CY2022Q3 us-gaap Assets
Assets
1864543000 usd
CY2021Q4 us-gaap Assets
Assets
1104429000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
18166000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1541000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
74317000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24441000 usd
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3586000 usd
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1746000 usd
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
13315000 usd
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
89419000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
109384000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
117147000 usd
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2833000 usd
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2530000 usd
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1491156000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
787255000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5418000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
544000 usd
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
28989000 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0 usd
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
129772000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
135211000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
135211000 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
135000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
138000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
13177000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
256347000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1836000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-620000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
85515000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58912000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
96991000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
196953000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1864543000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1104429000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
208976000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115830000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
478620000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
341307000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
47319000 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18589000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
97184000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
59826000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27193000 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
38596000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16705000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8486000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44041000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25564000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34467000 usd
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13169000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
105777000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36549000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
125684000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
40244000 usd
us-gaap Costs And Expenses
CostsAndExpenses
285598000 usd
us-gaap Costs And Expenses
CostsAndExpenses
121939000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
83292000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
75586000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
193022000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
219368000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
641000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
274000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
194000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
771000 usd
CY2022Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
2712000 usd
CY2021Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
2712000 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
20960000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
7514000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
1754000 usd
us-gaap Interest Expense
InterestExpense
12377000 usd
us-gaap Interest Expense
InterestExpense
5471000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
73707000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
74106000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
178127000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
193708000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12073000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-142481000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
33700000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-142232000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
61634000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
216587000 usd
us-gaap Net Income Loss
NetIncomeLoss
144427000 usd
us-gaap Net Income Loss
NetIncomeLoss
335940000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.45
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.39
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.44
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.28
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136527000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
142021000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137370000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
140815000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
139387000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146690000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
141019000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147652000 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
61634000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
216587000 usd
us-gaap Net Income Loss
NetIncomeLoss
144427000 usd
us-gaap Net Income Loss
NetIncomeLoss
335940000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
182000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1257000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-76000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
1000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-1000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-15000 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 usd
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
40000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
25000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
61815000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
216597000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
143211000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
335904000 usd
us-gaap Net Income Loss
NetIncomeLoss
144427000 usd
us-gaap Net Income Loss
NetIncomeLoss
335940000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
17174000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
15694000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3931000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2224000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
38596000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
6007000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2674000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-985000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1518000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-1727000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-80000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1573000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-997000 usd
halo Deferred Rent Payments
DeferredRentPayments
638000 usd
halo Deferred Rent Payments
DeferredRentPayments
568000 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
2712000 usd
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
20960000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-25329000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
142481000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-228000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-4000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
76186000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
14369000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
16021000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
14536000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-5152000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
14359000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6513000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
24209000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2306000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
157657000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
216924000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
225689000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
283354000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
725995000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
177833000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
999120000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2466000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1299000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-485259000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-106820000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
250000000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
250000000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
0 usd
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
120000000 usd
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
0 usd
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
120000000 usd
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
0 usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
784875000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
77453000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
369064000 usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
702000000 usd
halo Payment For Capped Call Transactions
PaymentForCappedCallTransactions
69120000 usd
halo Payment For Capped Call Transactions
PaymentForCappedCallTransactions
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
6465000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
424000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
200001000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
189737000 usd
halo Proceeds From Payments For Issuance Of Shares Share Based Payment Arrangement Including Option Exercised
ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised
7081000 usd
halo Proceeds From Payments For Issuance Of Shares Share Based Payment Arrangement Including Option Exercised
ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised
8226000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
356042000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
233876000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
28440000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
343980000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119219000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148203000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
147659000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
492183000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
319000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
102000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
970000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
318000 usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
639000 usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 usd
us-gaap Stock Issued1
StockIssued1
1019000 usd
us-gaap Stock Issued1
StockIssued1
7865000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
293171000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6797000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1693000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2636000 usd
CY2022Q3 halo Adjustment To Additional Paid In Capital Capped Call Transactions
AdjustmentToAdditionalPaidInCapitalCappedCallTransactions
69120000 usd
CY2022Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
200001000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
181000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
61634000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
96991000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
196953000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17174000 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1693000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7081000 usd
halo Adjustment To Additional Paid In Capital Capped Call Transactions
AdjustmentToAdditionalPaidInCapitalCappedCallTransactions
69120000 usd
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
200001000 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-1216000 usd
us-gaap Net Income Loss
NetIncomeLoss
144427000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
96991000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
119746000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5399000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4648000 usd
CY2021Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
64716000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
10000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
216587000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
281674000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
151047000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15694000 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
13104000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8226000 usd
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
189737000 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-36000 usd
us-gaap Net Income Loss
NetIncomeLoss
335940000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
281674000 usd
us-gaap Nature Of Operations
NatureOfOperations
Organization and Business <div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology (“ENHANZE”) with the partners’ proprietary compounds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first commercially approved product, Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant (“Hylenex”), and our ENHANZE partners’ approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in Hylenex and it works by breaking down hyaluronan (“HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the subcutaneous (“SC”) space. This temporarily reduces the barrier to bulk fluid flow allowing for improved SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (“IV”) drugs combined with our ENHANZE technology, data has been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Takeda Pharmaceuticals International AG and Baxalta US Inc. (“Takeda”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC (“Alexion”), argenx BVBA (“argenx”), Horizon Therapeutics plc. (“Horizon”), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (“ViiV”) and Chugai Pharmaceutical Co., Ltd (“Chugai”). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently receive royalties from three of these collaborations, including royalties from sales of one product from the Takeda collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of Halozyme and our partners to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our recent acquisition of Antares Pharma, Inc. (“Antares”), we also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to provide commercial or functional advantages such as convenience, improved tolerability, and enhanced patient comfort and adherence. Also, as a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ongoing product programs with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (“Teva”), Covis Group S.a.r.l. (“Covis”), Pfizer and Idorsia Pharmaceuticals Ltd. (“Idorsia”).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to the condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.’s wholly owned subsidiaries Antares Pharma IPL AG and Antares Pharma AG.</span></div>
halo Royalties Received Number Of Collaborators
RoyaltiesReceivedNumberOfCollaborators
3 collaborator
us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesThe preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 usd
halo Revenue Remaining Performance Obligation Period Of Termination By Written Notice
RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice
P90D
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12100000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
33700000 usd
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.068
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.187
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q2 us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
19700000 usd
CY2022Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
8700000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1850000 usd
CY2022Q2 us-gaap Goodwill
Goodwill
199481000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
120275000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
118425000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
622823000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
620000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
622203000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
6 security
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
118400000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1850000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
118425000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
500965000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
121238000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
118425000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
622203000 usd
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
236123000 usd
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
740910000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
208976000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115830000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
478620000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
341307000 usd
CY2022Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-500000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-1500000 usd
CY2022Q3 halo Accounts Receivableafter Allowancefor Credit Loss Currentexcluding Other Contract Assets
AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets
164135000 usd
CY2021Q4 halo Accounts Receivableafter Allowancefor Credit Loss Currentexcluding Other Contract Assets
AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets
90975000 usd
CY2022Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
69167000 usd
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0 usd
CY2022Q3 us-gaap Deferred Revenue
DeferredRevenue
6419000 usd
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
4276000 usd
CY2022Q3 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
6400000 usd
CY2022Q3 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
6400000 usd
CY2022Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
3600000 usd
CY2022Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
69200000 usd
CY2022Q3 halo Accountsreceivablefromproductsalestocollaborators
Accountsreceivablefromproductsalestocollaborators
51067000 usd
CY2021Q4 halo Accountsreceivablefromproductsalestocollaborators
Accountsreceivablefromproductsalestocollaborators
18504000 usd
CY2022Q3 halo Accountsreceivablefromcollaborators
Accountsreceivablefromcollaborators
3550000 usd
CY2021Q4 halo Accountsreceivablefromcollaborators
Accountsreceivablefromcollaborators
5422000 usd
CY2022Q3 halo Accountsreceivablefromroyalties
Accountsreceivablefromroyalties
95281000 usd
CY2021Q4 halo Accountsreceivablefromroyalties
Accountsreceivablefromroyalties
63555000 usd
CY2022Q3 halo Accountsreceivablefromproductsales
Accountsreceivablefromproductsales
6023000 usd
CY2021Q4 halo Accountsreceivablefromproductsales
Accountsreceivablefromproductsales
4634000 usd
CY2022Q3 us-gaap Other Receivables
OtherReceivables
9985000 usd
CY2021Q4 us-gaap Other Receivables
OtherReceivables
0 usd
CY2022Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
69167000 usd
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0 usd
CY2022Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
235073000 usd
CY2021Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
92115000 usd
CY2022Q3 halo Allowancefor Distribution Feesand Discounts
AllowanceforDistributionFeesandDiscounts
1771000 usd
CY2021Q4 halo Allowancefor Distribution Feesand Discounts
AllowanceforDistributionFeesandDiscounts
1140000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
233302000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
90975000 usd
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
11957000 usd
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
10672000 usd
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
56245000 usd
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
17451000 usd
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
35074000 usd
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
25785000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
103276000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
53908000 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
47783000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
47991000 usd
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
18695000 usd
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3809000 usd
CY2022Q3 us-gaap Other Assets
OtherAssets
10344000 usd
CY2021Q4 us-gaap Other Assets
OtherAssets
2096000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
76822000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
53896000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
25783000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
13414000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
51039000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
40482000 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
46148000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19891000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15080000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2003000 usd
CY2022Q3 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
36674000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13100000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31068000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6791000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5606000 usd
CY2021Q4 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
8794000 usd
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2000000 usd
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
700000 usd
CY2022Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
700000 usd
CY2021Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
400000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3900000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2200000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1700000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1200000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17904000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9858000 usd
CY2022Q3 halo Accruedmanufacturingexpenses
Accruedmanufacturingexpenses
6382000 usd
CY2021Q4 halo Accruedmanufacturingexpenses
Accruedmanufacturingexpenses
6514000 usd
CY2022Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
9409000 usd
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
1439000 usd
CY2022Q3 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
23310000 usd
CY2021Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
706000 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
15323000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3648000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7407000 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2820000 usd
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
79735000 usd
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24985000 usd
CY2022Q3 halo Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
5418000 usd
CY2021Q4 halo Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
544000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
74317000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24441000 usd
CY2022Q3 halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
100000 usd
CY2021Q3 halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
100000 usd
halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
300000 usd
halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
300000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
900000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
500000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2000000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1500000 usd
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1100000 usd
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
600000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
2700000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
2000000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
0 usd
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
199481000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
199481000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
927900000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
38596000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
889304000 usd
CY2022Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
59600000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
948904000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
27194000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
108771000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
108771000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
108771000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
108771000 usd
CY2022Q3 halo Finite Lived Intangible Asset Expected Amortization Yea After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour
427026000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
889304000 usd
us-gaap Debt Instrument Covenant Compliance
DebtInstrumentCovenantCompliance
in compliance
us-gaap Debt Instrument Covenant Compliance
DebtInstrumentCovenantCompliance
in compliance
CY2021Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
369100000 usd
CY2021Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
370200000 usd
CY2021Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
9080000.00 shares
CY2021 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
21000000 usd
CY2022Q3 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
77400000 usd
CY2022Q3 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
77600000 usd
CY2022Q3 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1510000 shares
CY2022Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
2700000 usd
us-gaap Debt Instrument Covenant Compliance
DebtInstrumentCovenantCompliance
in compliance
CY2022Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1538483000 usd
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
895936000 usd
CY2022Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
34012000 usd
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
19262000 usd
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
1504471000 usd
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
876674000 usd
CY2022Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
1385582000 usd
CY2021Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
878567000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6797000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5399000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17174000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15694000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6797000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5399000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17174000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15694000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
100000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
32500 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1600000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
700000 shares
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y8M12D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y8M12D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0266
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0339
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0066
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0089
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0137
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0339
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0089
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
550000000 usd
CY2019Q4 us-gaap Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
P3Y
CY2020 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
6500000 shares
CY2020 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
150000000 usd
CY2020 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
23.05
CY2021 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
4600000 shares
CY2021 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
200000000 usd
CY2021 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
43.02
CY2019Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
550000000 usd
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
22300000 shares
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
24.72
CY2021Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
750000000 usd
CY2022Q3 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
2100000 shares
CY2022Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
90200000 usd
CY2022Q3 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
109800000 usd
CY2022Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
CY2022Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
0
CY2022Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
0 usd
CY2022Q2 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
CY2022Q2 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
0
CY2022Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
0 usd
CY2022Q3 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
2093584 shares
CY2022Q3 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
43.09
CY2022Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
90207000 usd
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
2093584 shares
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
43.09
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
90207000 usd
halo Treasury Stock Acquired Fee Cost Per Share
TreasuryStockAcquiredFeeCostPerShare
0.02
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
61634000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
216587000 usd
us-gaap Net Income Loss
NetIncomeLoss
144427000 usd
us-gaap Net Income Loss
NetIncomeLoss
335940000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136527000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
142021000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137370000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
140815000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
139387000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146690000 shares
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.44
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.02
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
141019000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147652000 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.45
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.28
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25600000 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13600000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19000000.0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13500000 shares

Files In Submission

Name View Source Status
0001159036-22-000059-index-headers.html Edgar Link pending
0001159036-22-000059-index.html Edgar Link pending
0001159036-22-000059.txt Edgar Link pending
0001159036-22-000059-xbrl.zip Edgar Link pending
ex103-severancepolicy.htm Edgar Link pending
ex104halozymetherapeuticsi.htm Edgar Link pending
ex31110qq32022.htm Edgar Link pending
ex31210qq32022.htm Edgar Link pending
ex3210qq32022.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
halo-20220930.htm Edgar Link pending
halo-20220930.xsd Edgar Link pending
halo-20220930_g1.jpg Edgar Link pending
halo-20220930_g2.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
halo-20220930_def.xml Edgar Link unprocessable
halo-20220930_cal.xml Edgar Link unprocessable
halo-20220930_lab.xml Edgar Link unprocessable
halo-20220930_pre.xml Edgar Link unprocessable
halo-20220930_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending